The total liquefaction capacity of Asia and Oceania in 2015 was 112.4 mtpa. It is expected to increase from 112.4 mtpa in 2015 to 205.4 mtpa in 2020 at an AAGR of 12.1%. Asia and Oceania is expected to have a total planned regasification capacity of 11,762.3 bcf in 2020, accounting for 52.6% of the planned global regasification capacity. Further, the region is expected to have a total planned liquefaction capacity of 89.2 mtpa in 2020, and accounts for 11.2% of the planned global liquefaction capacity.
GlobalData’s LNG Industry Outlook in Asia and Oceania to 2020 – Capacity and Capital Expenditure Forecasts with Details of All Operating and Planned Terminals is a comprehensive report on the Asia and Oceania LNG industry. The report provides asset details of all active and planned, LNG liquefaction and regasification terminals in the region by country. Information by terminal includes terminal name, operator company name and design LNG processing capacity (liquefaction / regasification) for the period 2010–2020.
Published: March 2016, Single User Price: $5,000
Japan PET plant capacity has decreased from 0.328 MMTPA in 2005 to 0.325 MMTPA in 2014, at a negative CAGR of 0.1%. It is expected to remain the same as 0.325 MMTPA until 2019. Private companies dominate the PET sector in Japan. The major companies in the region are Mitsubishi Chemical Corporation, Mitsubishi Chemical Holdings Corporation, Mitsui & Co., Ltd., Teijin Chemicals Ltd., Toyobo Co., Ltd and Kanebo Gohsen, Ltd. Together these companies accounted for 96% of the PET capacity in Japan in 2014.
GlobalData’s Polyethylene Terephthalate (PET) Industry Outlook in Japan to 2019 – Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants report provides up to date in-depth information on Japan’s PET industry. The report presents major market trends. The report covers Japan’s PET plants and presents installed capacity information.
Published: Dec 2015, Single User Price: $1,000
South Africa and China to boost the Global Concentrated Photovoltaic Market by 2020
While China and the US are the largest CPV markets globally, South Africa is expected to make a significant impact on the global arena over the course of the forecast period. South Africa’s climatic conditions are highly suited to CPV technology, due to high Direct Normal Irradiance (DNI) rates throughout most of the country and the availability of vast expanses of land. South Africa’s CPV installed capacity will hit 193.3 MW by 2020, while China will lead the world with 582.3 MW by the end of the forecast period. The Chinese government has targeted 100 GW of installed solar capacity by 2020, but there has been speculation that the target will be revised to 200 GW.
GlobalData’s Concentrated Photovoltaic (CPV) Market, Update 2015 – Global Market Size, Competitive Landscape and Key Country Analysis to 2020 report provides analysis of historic and forecast statistics for cumulative and annual concentrated photovoltaic (CPV) capacity and annual electricity generation from 2006 to 2020.
Single User Price:$3,995 – Discounted price: $3,395
Vision care devices are one of the fastest growing segment in the ophthalmology industry. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vision Care pipeline products.
GlobalData’s Vision Care – Medical Devices Pipeline Assessment, 2015 report provides an overview of Vision Care currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development.
Published: Jan 2016, Single User Price: $4,000
India has the highest number of asthma sufferers in the Asia-Pacific (APAC) region. In 2014, 53.6 million people were estimated to be living with the disease, which is approximately 52.4% of the total assessed APAC prevalence. Lack of knowledge of the condition among the public, an increasing aging population, and increasing air and dust pollution will mean the prevalence rate will continue to rise over the period, resulting in 57 million sufferers by 2021. Despite this, India only represented 12.2% of the APAC asthma market, which reflects the low cost of therapy in comparison with the other assessed countries. Japan, by contrast, was the largest market of the five APAC countries in 2014 at $1.8 billion, and will continue its lead to 2021, growing to $3 billion at a CAGR of 7.1%, this reflects the relatively high cost of drugs, and the country’s readiness to adopt promising new molecules such as the IL-targeting mAbs.
GBI Research’s Asthma Therapeutics in Asia-Pacific Markets to 2021 – High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns report provides analysis of asthma treatment space across the Asia-Pacific region, including China, India, Australia, South Korea, and Japan. It includes annualized market data from 2014 and forecast to 2021, as well as epidemiology trends and information on new market entrants.
Published: March 2016, Single User Price: $4,995
The pharmaceutical sector is one of the most dynamic industries in the UK and is a major contributor to the country’s economy. The pharmaceutical market in the UK is set to grow from $28.8 billion in 2015 to approximately $43 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 8.4%, driven primarily by a robust life sciences industry. The pharmaceutical industry was the sixth largest contributor to the UK’s balance of trade, contributing $46.9 billion (£32.4 billion) to the economy in 2014, according to the Association of the British Pharmaceutical Industry.
The positive trends in the UK healthcare market can be attributed primarily to:
• Increasing elderly population
• Universal healthcare insurance
• High degree of access to healthcare facilities
GlobalData’s CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – UK report provides analysis of the pharmaceutical market landscape in the UK, and the impact of the current and emerging market access strategies used by the pharmaceutical industry for new and existing drugs. It discusses the regulatory requirements, key health insurance trends, government healthcare policies, and general industry trends.
This report includes:
• An overview of the pharmaceutical and medical devices market of the UK including the market size, market segmentation, key drivers and barriers.
• Profile and SWOT analysis of the major players in the pharmaceutical and medical devices market. The key players covered for the pharmaceutical market are Pfizer, GlaxoSmithKline, Novartis, Roche and Merck. The key players covered for the medical devices market are Essilor International, GlaxoSmithKline, DePuy Companies, Johnson & Johnson and B.Braun.
• Insightful review on the reimbursement and regulatory landscape. Analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices.
• A detailed analysis of the political and economic environment of the UK including the economic indicators, demographics, healthcare infrastructure and healthcare expenditure.
Price: $1,995 (Single User License)
Published: March 2016
Report Format: electronic pdf
The global adoption of telehealth technologies will potentially allow governments to make substantial savings on healthcare, while delivering important medical services to both rural and under-served communities. The telehealth market is being driven by the accelerated development of mobile technology and applications, a greater need for cost-effective healthcare, rising populations, and increased government funding. The Insurance Journal estimates that it could potentially deliver over $6 billion a year in healthcare savings in the US if the technology is widely adopted.
Telehealth could achieve substantial savings for a number of reasons, including the reduction of re-admissions linked to chronic conditions through mobile health monitoring technologies, a decrease in unnecessary use of emergency appointments through remote visits with nurses, and a lower amount of wasted capacity through telemedicine-based appointments.There is a wealth of opportunities to be exploited in the market. If telehealth providers are to realize these opportunities, they will have to develop compelling commercial models that seamlessly place their services within a wider system of integrated healthcare. Currently, the telemedicine and mobile health segments of the market are the ones to focus on, as they are some of the most promising and fast-growing across the board.
CBR Pharma’s latest report Telehealth: Global Market Trends, Regulatory Landscape and Operational Strategies report provides analysis of the global telehealth regulatory and market landscape, as well as its main applications in healthcare and associated sectors. It includes information on regulations and guidelines in key geographies including the US, Europe, Japan, China, India and South Africa, along with global market drivers and restraints.
Key questions answered:
• What impact will telehealth technologies have on healthcare systems, patients and related sectors?
• What strategies are healthcare providers considering when implementing new telehealth programs?
• How does the telehealth regulatory and market landscape compare in the developed markets of the US, Europe and Japan, compared with that of emerging economies like India, China and South Africa?
• What technological, macroeconomic and industry factors are driving or restraining the telehealth market?
• What are the most important factors to consider when designing and implementing a new telehealth program?
• What are the most pertinent considerations for all telehealth programs?
• What telehealth devices represent the biggest commercial opportunities and what are their key features?
Price: $2,995 (Single User License)
Published: Mar – 2016
Report Format: electronic pdf